Showing 3411-3420 of 5291 results for "".
- FDA Approves Galderma's Restylane Kysse for Lip Augmentation and Upper Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-kysse-for-lip-augmentation-and-upper-perioral-rhytids-1/2460374/The FDA has approved Galderma'a Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is the first hyaluronic acid (HA) filler specifically indicated for the lips using XpresHAn Technology globally referred to as the OB
- Cutera's TruSculpt Flex Wins 2020 Good Housekeeping Awardhttps://practicaldermatology.com/news/cuteras-trusculpt-flex-wins-2020-good-housekeeping-award/2460373/Congrats! Cutera’s truSculpt flex won a Good Housekeeping 2020 Beauty Award Winner for Ultimate Body Product. truSculpt flex is FDA-cleared for the improvement of abdominal tone, strengthening of the abdominal muscles, and development of a firmer abdomen. It is also cleared for th
- La Fondation La Roche-Posay (North American) Awards 2020 Grant Winnershttps://practicaldermatology.com/news/la-fondation-la-roche-posay-north-american-awards-2020-grant-winners/2460363/And the five La Fondation La Roche-Posay (North America) 2020 research grant winners in the field of dermatology are… Dawn Zhang Eichenfield, MD, PhD, Chief Dermatology Resident at the University of California, San Diego. She received the first place pr
- Industry Responds to COVID-19: UCB, Galderma, Timeless Skin Carehttps://practicaldermatology.com/news/industry-responds-to-covid-19-ucb-galderma-timeless-skin-care/2460354/UCB. UCB is working with the Seattle Structural Genomics Center for Infectious Disease to identify crystal structures of SARS-CoV-2 proteins. In addition to provi
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant
- Isdin Taps Professional Golfer Jessica Korda As New Sports Ambassadorhttps://practicaldermatology.com/news/isdin-taps-professional-golfer-jessica-korda-as-new-sports-ambassador-1/2460330/Professional golfer and LPGA star Jessica Korda is ISDIN’s new sports ambassador. As part of the campaign, Korda is sharing how she keeps her skin looking its best on and off the golf course with ISDIN products. "ISDIN formulates unique and innovative products with
- New AAAHC COVID-19 Guidelines Call for Postponing Elective or Non-Essential Visits and Surgerieshttps://practicaldermatology.com/news/new-aaahc-covid-19-guidelines-call-for-postponing-elective-or-non-essential-visits-and-surgeries/2460323/The Accreditation Association for Ambulatory Health Care (AAAHC) is calling for the postponement of elective or non-essential visits or surgeries in their newly released guidelines. For patients that require an office visit, increas
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- FDA Grants Breakthrough Status for Baricitinib in AAhttps://practicaldermatology.com/news/fda-grants-breakthrough-status-for-baricitinib-in-alopecia-1/2460308/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Eli Lilly and Company and Incyte Corporation’s baricitinib for the treatment of alopecia areata (AA). Baricitinib is currently approved for the treatment of adults with moderately to severe
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is